{"analyses":[{"ciLowerLimit":"0.374","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.649","groupDescription":"Teff-high Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.492","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.517","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.720","groupDescription":"ITT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.610","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.1","upperLimit":"13.0","value":"11.3"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"7.3","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Teff-high Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.9","upperLimit":"9.8","value":"8.3"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"7.1","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"title":"ITT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"description":"PFS, as determined by the investigator according to RECIST v1.1, in Arm B versus C in the Teff high population and ITT population.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG000","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG001","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"Teff-high population is defined as the patients in the ITT population with Teff signature expression \\>=-1.91. ITT population is defined as all randomized patients, regardless of receipt of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)","title":"PFS, as Determined by the Investigator in Arm B Versus Arm C in Teff High Population and ITT Population","type":"SECONDARY","unitOfMeasure":"Months"}